Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-001
- Development stage
- Preclinical
- Lead developer
- EBViously
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EBV-001 is a multi-antigen, DNA-free virus-like particle (VLP) vaccine candidate developed by EBViously, a spin-off from Helmholtz Munich and the German Center for Infection Research (DZIF). The vaccine is designed to mimic the complexity of the Epstein-Barr virus (EBV) by presenting more than 50 viral antigens, including a previously overlooked protein, in their authentic structural conformation. These empty VLP shells lack viral genetic material, ensuring they are non-infectious while eliciting a broad and potent humoral and cellular immune response. EBV-001 is primarily being developed to prevent infectious mononucleosis (IM) and associated post-infectious fatigue (ME/CFS). Additionally, it is being explored for the prevention of EBV-associated cancers, post-transplant lymphoproliferative disease (PTLD), and potentially reducing the risk of multiple sclerosis (MS), for which IM is a known risk factor.
- Other names
- next-generation virus-like particle vaccineEBViously vaccine candidate
02
Targets
EBNA1 (Epstein-Barr virus latency proteins)
Beyond the preview
Go deeper on EBV-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-001.